

AURA BIOSCIENCES

Developing the Next
Generation of
Nano-delivered Drugs



A Global Start-up

1. Incorporated in Delaware Jan 2009, Headquarters in Boston
2. Licensed Technology from three European Research Institutions
3. Seed round = \$3.5MM
4. Built Leadership Team in Cambridge (MA)
5. Novel Technology to create a next generation of Nano-drugs
6. Company awarded **TECH PIONER 2010 WORLD ECONOMIC FORUM**

Licensing Technology in Europe

Advantages

Top research institutions
and scientists

Top peer reviewed publications

Reduced Biotech competition

TTOs willingness to transfer to
biotech

Less pressure on terms

Challenges

No big Biotech Clusters

Poor budget for patents

Legal differences among countries to
set up the agreements

Administration is very slow

Grants limited to local governments

Global R&D Collaborations



Aura is a Global start up with collaborations all over the world

Benefits of Global R&D Collaborations

1. Avoid the cost & risk of building a big R&D facility in house
2. Develop several projects in parallel without increasing R&D staff
3. Avoid the cost of buying expensive equipment that is needed temporarily
4. Leverage the expertise of a Research Group to accelerate development
5. Validation of results by an external lab
6. Leverage the Relationship with Top opinion leaders in the field
7. Obtain additional IP in the field

GLOBAL GRANTS.....

1. European Grants:

- Require collaboration between several research institutions, countries and companies
- Highly bureaucratic
- Company MUST be European
- Country requirements: MUST create employment within the country

2. US Grants:

- Company MUST be American
- Investors MUST be over 50% US